Equities research analysts expect Keryx Biopharmaceuticals (NASDAQ:KERX) to post sales of $21.12 million for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Keryx Biopharmaceuticals’ earnings. The lowest sales estimate is $19.09 million and the highest is $22.95 million. Keryx Biopharmaceuticals reported sales of $11.82 million during the same quarter last year, which indicates a positive year-over-year growth rate of 78.7%. The firm is expected to issue its next quarterly earnings results on Thursday, May 3rd.
On average, analysts expect that Keryx Biopharmaceuticals will report full year sales of $21.12 million for the current financial year, with estimates ranging from $99.97 million to $114.31 million. For the next year, analysts expect that the company will post sales of $162.01 million per share, with estimates ranging from $159.00 million to $163.88 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that cover Keryx Biopharmaceuticals.
Keryx Biopharmaceuticals (NASDAQ:KERX) last announced its earnings results on Wednesday, February 7th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.08). Keryx Biopharmaceuticals had a negative return on equity of 10,954.62% and a negative net margin of 269.52%. The firm had revenue of $18.70 million for the quarter, compared to the consensus estimate of $17.53 million. During the same period in the prior year, the business earned ($0.32) EPS. Keryx Biopharmaceuticals’s quarterly revenue was up 96.8% on a year-over-year basis.
KERX has been the subject of a number of analyst reports. Morgan Stanley lowered their target price on shares of Keryx Biopharmaceuticals from $7.00 to $6.00 and set an “equal weight” rating for the company in a research note on Thursday, February 8th. Zacks Investment Research raised shares of Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, December 1st. BidaskClub raised shares of Keryx Biopharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, February 24th. Finally, ValuEngine downgraded shares of Keryx Biopharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, February 22nd. Two analysts have rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $7.19.
Keryx Biopharmaceuticals stock opened at $4.53 on Monday. Keryx Biopharmaceuticals has a 52 week low of $4.01 and a 52 week high of $8.38. The company has a quick ratio of 2.49, a current ratio of 3.12 and a debt-to-equity ratio of -8.87.
In other Keryx Biopharmaceuticals news, COO Christine A. Carberry sold 9,048 shares of the firm’s stock in a transaction on Thursday, January 18th. The shares were sold at an average price of $4.87, for a total value of $44,063.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Scott A. Holmes sold 5,651 shares of the firm’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $4.81, for a total transaction of $27,181.31. The disclosure for this sale can be found here. Insiders sold 43,182 shares of company stock valued at $208,175 over the last 90 days. Corporate insiders own 2.58% of the company’s stock.
A number of large investors have recently bought and sold shares of the business. MetLife Investment Advisors LLC acquired a new stake in Keryx Biopharmaceuticals in the fourth quarter worth $187,000. Cornerstone Capital Management Holdings LLC. acquired a new stake in Keryx Biopharmaceuticals in the fourth quarter worth $192,000. Teachers Advisors LLC grew its holdings in Keryx Biopharmaceuticals by 9.1% in the fourth quarter. Teachers Advisors LLC now owns 164,003 shares of the biopharmaceutical company’s stock worth $763,000 after purchasing an additional 13,676 shares during the period. Deutsche Bank AG grew its holdings in Keryx Biopharmaceuticals by 103.2% in the fourth quarter. Deutsche Bank AG now owns 205,933 shares of the biopharmaceutical company’s stock worth $956,000 after purchasing an additional 104,585 shares during the period. Finally, Clearbridge LLC grew its holdings in Keryx Biopharmaceuticals by 67.7% in the fourth quarter. Clearbridge LLC now owns 2,692,744 shares of the biopharmaceutical company’s stock worth $12,521,000 after purchasing an additional 1,087,120 shares during the period. Institutional investors and hedge funds own 65.36% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Brokerages Anticipate Keryx Biopharmaceuticals (KERX) Will Announce Quarterly Sales of $21.12 Million” was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://ledgergazette.com/2018/03/19/brokerages-anticipate-keryx-biopharmaceuticals-kerx-will-announce-quarterly-sales-of-21-12-million.html.
Keryx Biopharmaceuticals Company Profile
Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.